Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21857652 | 0.90 | GAA (0.42) | GAASMN1; SMN2LMNAABL1HTT | |
| SCHEMBL19554378 | 0.84 | KDM4E (0.48) | GAATSHRABL1KDM4ENQO2 | |
| SCHEMBL28183743 | 0.83 | ABL1 (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL149267 | 0.76 | GAA (0.44) | GAATSHRABL1KDM4ENQO2 | |
| SCHEMBL7415528 | 0.76 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28183719 | 0.75 | GAA (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19993696 | 0.75 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29848825 | 0.75 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28421442 | 0.75 | ALDH1A1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13277020 | 0.75 | ABL1 (0.49) | SMN1; SMN2LMNAABL1HTTNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108984-B2 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108984-B2 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108984-B2 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2012125629-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | CA12 4866/4885CA1 4869/4885CA2 4602/4885 |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PDPK1, PIK3CD | CA12 4838/4885CA1 4567/4885CA2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.